Zimeldine treatment of obsessive‐compulsive disorder

Abstract
ABSTRACT– Six patients with Obsessive‐Compulsive Disorder (DSM III) were treated in an open uncontrolled trial with Zimeldine, for 8 weeks. All six patients had cognitive deficits before treatment. Five patients improved on the clinical symptoms. Four of these showed pronounced amelioration of their cognitive deficits.

This publication has 4 references indexed in Scilit: